Resources

• The benefits of vaccination.
  - Economist 2005.
  Economist Newspaper
  Describes a study which looked at two vaccination programmes and attempted to calculate the wider benefits in terms of protection from diseases and of costs avoided.
• Childhood Vaccine Purchase Costs in the Public Sector: Past Trends, Future Expectations. (PDF: 192k)
  Davis Matthew M., Zimmerman Jessica L., Wheeler John R. C., Freed Gary L.
  - American Journal of Public Health 92(12):1982-1987.
  » PubMed: 12453820
  The cost per child for recommended vaccines at public-sector prices may triple over the next 2 decades. These projections have implications for vaccine financing at federal and state levels.
• Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
  Nichol Kristin L.
  - Archives of Internal Medicine 2001;161(5):749-59.
  American Medical Association
  » PubMed: 11231710
  Assesses the economic implications of a strategy for annual vaccination of healthy working adults aged between 18 and 64 years.
• Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. (PDF: 160k)
  Lee Patrick Y., Matchar David B., Clements Dennis A., Huber Joel, Hamilton John D., Peterson Eric D.
  - Annals of Internal Medicine 2002;137(4):225-31.
  American College of Physicians
  » PubMed: 12186512
  Compares the relative health values of contemporary treatment strategies for influenza in a healthy sample of working adults.
• Economics of childhood immunizations in Canada : data book. (PDF: 521k)
  Institute of Health Economics; 2007
  Collates existing data in order to draw a picture of the current status of childhood immunization economics.
• Effectiveness and cost-benefit of influenza vaccination of healthy working adults : a randomized controlled trial.
  Bridges Carolyn Buxton, Thompson William W., Meltzer Martin I., Reeve Gordon R., Talamonti Walter J., Cox Nancy J., Lilac Heather A., Hall Henrietta, Klimov Alexander, Fukuda Keiji.
  - JAMA : Journal of the American Medical Association 2000;284(13):1655-63.
  American Medical Association
  » PubMed: 11015795
  Evaluates the effectiveness and cost-benefit of influenza vaccine in preventing influenza-like illness (ILI) and reducing societal costs of ILI among healthy working adults.
• Impact of vaccine cost and information about complications of varicella on parental decision regarding varicella vaccine. (PDF: 124k)
  De Serres Gaston, Duval Bernard, Boulianne Nicole.
  - Canadian Journal of Public Health 2002;93(2):114-6.
  Canadian Public Health Association
  » PubMed: 11963514
  Assesses the influence of providing information about complications of disease and vaccine cost on parental decision to vaccinate against varicella.
• Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
  Trotter Caroline L., Edmunds W. John.
  - BMJ 2002;324(7341):809.
  BMJ
  » PubMed: 11934772
  Assesses the cost effectiveness of a meningococcal serogroup C conjugate vaccination campaign in 0-17 year olds.
• Vaccine Research, Development and Awareness: Front Line Medicine. (PDF: 2.1m)
  Globe and Mail .
  Globe and Mail; 2010
  With a proud history of health research and promotion, and ongoing contributions to the development and distribution of disease-fighting vaccines, Canada is well positioned to put our health innovation and expertise to even fuller benefit for the world and our society and economy. Coudl this be just the shot in the arm Canada needs? Proponents say yes, and are encouraging the public to tune into the benefits.